🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. Piqray 50 mg and 200 mg film-coated tablets

    Wuhan Createrna Science and Technology Co., Ltd

    metasatic breast cancer, hormon positive, her 2 negative

    phase 2 small molecule active

    1 trial

  2. Placebo

    NovaBridge Biosciences

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  3. Placebo

    Cardiff Oncology

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  4. Placebo for ponsegromab (PF-06946860) solution for injection, Ponsegromab (PF-06946860)

    Pfizer Australia Pty Ltd

    Cancer cachexia

    phase 2 small molecule active

    1 trial

  5. Pluvicto 1 000 MBq/mL solution for injection/infusion

    Ningbo Cancer Hospital

    Clear Cell Renal Cell Carcinoma (ccRCC)

    phase 2 small molecule active

    1 trial

  6. Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation

    Novartis Pharmaceuticals

    Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with moderate and severe renal impairment and with normal renal function.

    phase 2 small molecule active

    1 trial

  7. Pre-operative chemotherapy

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  8. Pre-operative chemotherapy

    Nanjing Zenshine Pharmaceuticals

    Gastric Cancers

    phase 2 small molecule active

    1 trial

  9. Precision Cells

    Ningbo Cancer Hospital

    Precision Cell Immunotherapy

    phase 2 mab active

    1 trial

  10. Pred Forte 10 mg/ml colirio en suspensión, Pred Forte 1% w/v, Eye Drops Suspension, Brimonidine Tartrate 0.2% w/v Eye Drops., Alphagan 2 mg/ml colirio en solución, IMGN151

    AbbVie Deutschland GmbH & Co. KG

    Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (EOC), recurrent cervical cancer

    phase 2 small molecule active

    1 trial

  11. ProSpare

    United Therapeutics Europe Ltd

    Cancer

    phase 2 other active

    1 trial

  12. Prostate alone IMRT

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 2 other active

    1 trial

  13. Pucotenlimab

    Sun Yat-sen University

    Colorectal Cancer (CRC)

    phase 2 small molecule active

    1 trial

  14. Pucotenlimab

    Zhejiang Provincial People's Hospital

    Pancreatic Cancer

    phase 2 mab active

    1 trial

  15. Pulmonary Rehabilitation (PR)

    United Therapeutics Europe Ltd

    Non-small Cell Lung Cancer Stage III

    phase 2 other active

    1 trial

  16. Puregon 300 IU/0.36 mL solution for injection, Cetrotide 0.25 mg powder and solvent for solution for injection, NOLVADEX 10 mg, comprimé pelliculé, Ovitrelle 250 micrograms solution for injection in pre-filled pen

    CERO THERAPEUTICS HOLDINGS, INC.

    Breast cancer

    phase 2 small molecule active

    1 trial

  17. Pyrotinib

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  18. Pyrotinib, trastuzumab, paclitaxel-albumin

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  19. QL1706

    The First People's Hospital of Lianyungang

    Local Advanced Esophageal Cancer

    phase 2 small molecule active

    1 trial

  20. QL1706

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Platinum-resistant Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  21. QL1706 (Iparomlimab/Tuvonralimab)

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 2 small molecule active

    1 trial

  22. Quemliclustat

    Arcus Biosciences

    Oligometastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  23. REGN15505

    Regeneron UK Limited

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  24. REGN2810

    Regeneron UK Limited

    Prostate Cancer Metastatic

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources